The gene coding for SecA from Enterococcus faecalis was cloned and overexpressed in Escherichia coli. In this protein, the lysine at position 6 was replaced by an asparagine in order to reduce sensitivity towards proteases. The modified protein was purified and crystallized. Crystals diffracting to 2.4 Å resolution were obtained using the vapour-diffusion technique. The crystals belong to the monoclinic space group C2, with unit-cell parameters a = 203.4, b = 49.8, c = 100.8 Å , = = 90.0, = 119.1
Introduction
In bacteria, preprotein transport across the inner membrane is assisted by the multisubunit protein complex translocase, consisting of the heterotrimeric membrane protein SecYEG and the peripheral membrane-associated SecA (de Keyzer et al., 2003) . SecA is an ATPdependent molecular motor that drives the movement of preproteins through the SecYEG translocon in a stepwise fashion concomitant with large conformational changes and with its own membraneinsertion/deinsertion reaction coupled to ATPase activity.
Although a wealth of data is available on the genetics and biochemistry of SecA (Vrontou & Economou, 2004) and the crystal structures of the SecA proteins from Bacillus subtilis (Hunt et al., 2002; Osborne et al., 2004) and Mycobacterium tuberculosis (Sharma et al., 2003) have been described, the oligomeric state of the active protein is still a subject of controversy. In solution, SecA forms a homodimer under physiological conditions. It has been described as being translocation-active in a dimeric state (Driessen, 1993; de Keyzer et al., 2005) , while other studies have proposed the dissociation of the dimer during translocation (Duong, 2003; Or et al., 2005) . Several lines of evidence indicate that depending on salt, temperature (Woodbury et al., 2002) , specific lipids and signal peptide analogues (Benach et al., 2003) , SecA exists in a dynamic equilibrium of monomeric, dimeric and higher oligomeric states.
SecA is essential in bacteria and there is no SecA analogue in human or animals. Thus, it represents a potential target for antimicrobial agents. Increasing resistance of pathogenic bacteria towards common antibiotics makes it necessary to develop new agents for the therapy of infectious diseases. For this purpose, the knowledge of the three-dimensional structure of the target protein is a prerequisite. The pathogenic microorganism Enterococcus faecalis presently causes the majority of human enterococcal infections and is therefore a suitable target for antimicrobial therapy (Huycke et al., 1998) . In this paper, we describe the cloning, overexpression and crystallization of the SecA protein from E. faecalis.
Materials and methods

Cloning, expression and purification
The secA gene was amplified by PCR using E. faecalis DNA as template and the oligonucleotides EFSecA-NcoI and EFSecAHindIII as primers. The amplificate (2563 bp) was digested with NcoI and HindIII. The resulting fragment was purified and ligated to the plasmid expression vector pNCO113 (Stueber et al., 1990 ) previously treated with the same restriction enzymes, affording the expression plasmid pNCO-EFSecA.
The plasmid pNCO-EFSecA served as a template for a PCR with the oligonucleotides EFSecA-K6N-NcoI and EFSecA-XcmI-271 as primers. Both the purified PCR product (294 bp) and the vector pNCO-EFSecA were digested with the restriction endonucleases NcoI and XcmI, yielding fragments with 260 and 5670 bp, and were then ligated together. The resulting plasmid (pNCO-EFSecA-K6N) was used as a template for PCR with the oligonucleotides EFSecASplI-2240 and EFSecA-HIS6-HindIII as primers. The amplificate (356 bp) and the vector pNCO-EFSecA-K6N were digested with the restriction endonucleases SplI and HindIII, yielding fragments of 332 and 5621 bp, and were ligated together, yielding the expression plasmid pNCO-EFSecA-K6N-C-HIS6.
All ligation mixtures were transformed into Escherichia coli strain XL-1 Blue. Plasmids reisolated from XL-1 strains were sequenced using the method of Sanger (GATC Biotech, Konstanz, Germany; for oligonucleotides, strains and plasmids, see supplementary material 1 ). The reisolated plasmid pNCO-EFSecA-K6N-C-HIS6 was transformed into M15(pREP4) E. coli competent cells, affording the recombinant E. coli strain M15(pREP4)-pNCO-EFSecA-K6N-C-HIS6. The cells were grown at 310 K to an OD 600 nm of 0.7 in LB medium, induced with 2 mM IPTG and incubated for 3 h. Cells were harvested, washed in 50 mM Tris-HCl pH 7.5, 20% glycerol and stored at 253 K. Cells were resuspended in 50 mM Tris-HCl, 1 mM PMSF, 20% glycerol and sonicated (5 Â 30 s) followed by ultracentrifugation at 40 000 rev min À1 in a Ti-70 rotor (Beckman). The protein EFSecA-K6N-HIS6 was purified by affinity chromatography on Ni-NTA agarose (HisTrap, Amersham Biosciences) with a linear gradient of 10-500 mM imidazole in 50 mM Tris-HCl pH 7.5 and 10% glycerol. All data described in this paper were obtained from EFSecA-K6N-HIS6, which is hereafter referred to as EFSecA.
Selenomethionine labelling of the EFSecA was performed as described by Bader et al. (2004) 
Crystallization
For crystallization experiments, a solution of 10 mg ml À1 EFSecA in 50 mM Tris-HCl pH 7.5, 50 mM NaCl and 10%(v/v) glycerol was used. In initial crystallization attempts, commercial screens from Hampton Research (Crystal Screen, Crystal Screen 2, Crystal Screen Lite, Membfac and Natrix) were tested. Crystallization experiments were performed at 293 K using the vapour-diffusion technique with sitting drops equilibrated against 1 ml reservoir solution. The conditions in the initial screenings which promoted crystallization were retested and optimized. All experiments were designed and monitored using the program XtalBase (W. Meining; http:// www.xtalbase.net). In cocrystallization experiments with AMP-PNP and ADP, 0.5 ml of a 10 mM solution of the respective ligand was added to 1 ml protein solution and 1 ml reservoir solution.
Data collection and preliminary crystallographic analysis
Diffraction data were collected on the I711 beamline at MAX-Lab (Lund, Sweden) equipped with an Oxford Cryosystem and a MAR Research imaging plate. Prior to data collection, crystals of interest went through three cycles of a gradual exchange of the mother liquor by a solution containing 25%(v/v) PEG 8000, 300 mM sodium cacodylate pH 6.5, 100 mM magnesium acetate and 10%(v/v) PEG 400. The crystals were then placed in a nylon loop and flash-cooled to 105 K. Two data sets, one to a resolution limit of 2.4 Å and another one to 3.5 Å , were collected from a single crystal at a wavelength of 1.092 Å and a temperature of 105 K under atmospheric pressure. The oscillation ranges were 1 and 5 , respectively, and exposure times were approximately 30 s. The data were indexed, scaled and merged using the HKL package programs XDISP, DENZO and SCALE-PACK (Otwinowski & Minor, 1997) . The program Phaser was used for attempts to determine phases via molecular replacement (Read, 2001 ).
Results and discussion
Protein expression and purification
Plasmids carrying the engineered gene EFSecA-K6N-C-HIS6 under the control of a T5 promotor and lac operator directed the synthesis of a 97 kDa protein in a recombinant E. coli strain. Expression and purification of the wild-type EFSecA (845 amino acids) yielded peptides lacking the N-terminal five and six amino acids as determined by mass spectroscopy. Because of the presence of a lysine-lysine motif in the amino-acid sequence at position 6 and 7, the wild-type protein appeared to be highly sensitive to proteolysis at this position. Mimicking the sequence of B. subtilis SecA, lysine 6 was replaced by an asparagine (K6N mutant). Edman degradation showed an intact N-terminus of the K6N mutant. A hexahistidine tag was introduced at the C-terminus to allow rapid purification and the resulting peptide was used in crystallization trials.
To determine the quaternary structure, EFSecA was analyzed by analytical ultracentrifugation and size-exclusion chromatography. Molecular weights in the region of 110 kDa were found, indicating the monomeric state of the protein. Electron microscopy of negatively stained EFSecA showed particles with a diameter of 5-6 nm, in agreement with the monomeric form. In the absence of reducing agents, protein preparations also contained also a small fraction of dimeric species which could be separated by size-exclusion chromatography or native gel electrophoresis. In the presence of 10 mM DTT the dimeric species disappeared, indicating the reduction of an intermolecular disulfide bridge. The existence of a stable monomeric form of the SecA protein from E. faecalis is in contrast to the dimeric proteins from E. coli and B. subtilis observed under similar conditions (Driessen, 1993; Takamatsu et al., 1992; Ding et al., 2003) .
Crystallization
EFSecA was crystallized in sitting drops via the vapour-diffusion method. The largest crystals were obtained when 1 ml reservoir solution (15-30% PEG 8000, 0.1-0.3 M sodium cacodylate pH 6.5, 0.1-0.4 M magnesium acetate) was mixed with 1 ml protein solution [10 mg ml À1 EFSecA in 50 mM Tris-HCl pH 7.5, 50 mM NaCl and 10%(v/v) glycerol] and equilibrated against 1 ml reservoir solution.
In successful experiments, the crystallization drops developed phase separation within 6 d and plate-shaped crystals with an edge length of up to 800 mm within two weeks (Fig. 1 ). Crystals were also obtained in the presence of ADP and grew under similar conditions to the native protein. However, these crystals diffracted X-rays to a resolution of only about 8 Å . Crystals were also obtained by cocrystallization with AMP-PNP. These crystals were generally twinned and were too small for data collection.
X-ray diffraction experiments
Crystals of EFSecA diffracted X-rays to 2.4 Å , but were merged to 2.7 Å , as the merging statistics indicated an increased R merge and a fall-off of I/(I) to below 1 at higher resolution (Table 1 ). The crystal lattice was determined to be monoclinic and the space group was C2, with unit-cell parameters a = 203.4, b = 49.8, c = 100.8 Å , = = 90.0, = 119.1 . The corresponding unit-cell volume is 892 243 Å and the Matthews coefficient calculated for one molecule per asymmetric unit is V M = 2.3 Å 3 Da À1 , corresponding to 46.5% solvent content. The assumption of one molecule seems reasonable, as the calculated V M is close to the most probable V M found in proteins (Kantardjieff & Rupp, 2003; Matthews, 1968) and because the sample was found to be monomeric in electrophoresis and electron-microscopic studies. In attempts to solve the structure via molecular replacement, various models originating from the published structures of SecA from B. subtilis (PDB code 1m6n; Hunt et al., 2002) and M. tuberculosis (PDB code 1nkt; Sharma et al., 2003) were used as search models. These attempts resulted in a unique properly packed clear solution, but with resulting electron density of only moderate quality. The density did not improve upon density modification. The nucleotidebinding domains I and II were generally best defined, whereas other domains or parts of them were ill-defined or not even visible (e.g. the extended helix in the helical scaffold domain). In total, only about 30% of the density allowed the determination of the approximate location and orientation of individual residues. The lack of acceptable density prompted us to attempt solving the structure using anomalous diffraction data collected from crystals grown from SeMet-enriched SecA. Such a modified SecA sample has been prepared and is currently being tested for crystallization.
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